
## Management of Inflammatory Bowel Disease in 2022

"The Story of Laura"

Ashwin N Ananthakrishnan, MD, MPH Associate Professor of Medicine Massachusetts General Hospital



June 2022



# **Financial Disclosures**

- Scientific Advisory Boards
  - Iterative Scopes
  - Menten Al

# **Learning Objectives**

\_ To understand the diagnostic and therapeutic algorithm for IBD

 To discuss the efficacy and safety of treatments for the management of IBD

# "Laura"

- 19 year old female college student
- 3 months history of <u>bloody diarrhea</u>, <u>5-8 times per day</u>, 2 times at night.
- \_ Intermittent crampy abdominal pain associated with a BM
- \_ Non-smoker
- No family history of IBD
- \_ Abdominal exam reveals mild Lt LQ tenderness.
- Physical exam is unremarkable
- Laboratory findings include mild anemia (<u>Hb 11</u>, MCV 79).
  Albumin is <u>3.4 g/dL</u>

# "Laura"

 You recommend a colonoscopy but Laura is reluctant to have an invasive procedure.

\_ "Are there other tests that can help establish a diagnosis?"

## **Non-invasive tests for IBD**

#### Fecal calprotectin and Lactoferrin

- Non-specific markers of gastrointestinal inflammation
- Does not differentiate from other inflammatory GI diseases
- Can also be used to monitor inflammation in those with established IBD

Fecal Calprotectin Cut-off	Sensitivity	Specificity
50 µg/g	0.92 (0.90-0.94)	0.60 (0.52-0.67)
100 µg/g	0.84 (0.80-0.88)	0.66 (0.59-0.73)
250 μg/g	0.80 (0.76-0.84)	0.82 (0.77-0.86)

# "Laura"

 You suspect underlying inflammatory bowel disease and recommend a colonoscopy.


Colonoscopy:

- Confluent inflammation from anus to splenic flexure with erythema and granularity
- Normal terminal ileum

You decide to image her small bowel to rule out more proximal involvement given her abdominal pain

### Imaging in IBD CT enterography

- CT scan with IV contrast and <u>large volumes of neutral oral</u> contrast to achieve luminal distention
- Allows for better mucosal resolution (active inflammation), obstructive lesions (by distending lumen)
- Less useful for extra-luminal complications




### Imaging in IBD **CT enterography**

Active inflammation

- Mural hyperenhancement
- Mural stratification
  - Acute (water), chronic (fat)
- Engorged vasa recta
- Fat stranding
- **Fistulas**





### Imaging in IBD MR enterography

- No radiation exposure
- Similar (or slightly superior) performance as CTE for assessment of active inflammation



### Management of IBD Therapeutic Goals in IBD

Normal bowel function and improved quality of life (QOL)

Induce remission rapidly

Maintain steroid-free remission over time (deep remission)

Modify long-term outcomes of the disease

- Avoid hospitalization and surgery
- Eliminate disability
- Minimize exposure to steroids

### Management of IBD **Probiotics and Antibiotics**

#### **Probiotics**

- No evidence of efficacy in Crohn's disease
- VSL#3 is effective in inducing and maintaining remission in mild-to-moderate ulcerative colitis

#### Antibiotics

 Effective for treating abscesses and preventing postoperative recurrence in Crohn's disease (metronidazole)
 Single RCT demonstrated benefit for rifaximin in ileal Crohn's disease

### Management of IBD Fecal transplantation

- Four randomized controlled trials in ulcerative colitis
  - Three demonstrated benefit
    - Daily enema therapy x 6 weeks
    - Colonoscopic FMT once a week for 6 weeks
  - No benefit in a third trial with FMT via NG tube administration
  - There likely is a donor effect
  - No evidence of efficacy in Crohn's disease (except for case series)

### Management of IBD 5-Aminosalicylates

<u>Mechanism:</u> Local anti-inflammatory effect on the small intestine and colon

#### <u>Pros</u>

- Asacol HD® (mesalamine), Lialda ®, Apriso®, sulfasalazine, balsalazide (colazal ®)
- Available in oral and topical formulations (enemas, suppositories) for local therapy
- No systemic immunosuppression
- Effective in mild-to-moderate ulcerative colitis
- Limited (No) efficacy in Crohn's disease

### Management of IBD Steroids, Immunomodulators


#### <u>Steroids</u>

- Very effective for induction of remission
- Also available as <u>controlled-release formulations</u> budesonide (Entocort®)
- No role in maintenance of remission
- Associated with significant long-term consequences


#### Immunomodulators

- Azathioprine, 6-MP, methotrexate
- Effective for moderate severity disease
- Not effective for induction of remission (lag of 6-8 weeks of onset of action)

### Management of IBD Biologics and Small Molecules



### Management of IBD Anti-TNF biologics



### Management of IBD Other Biologics

#### Vedolizumab:

- Monoclonal antibody against  $\alpha 4\beta 7$  integrin.
- Approved for use in both Crohn's disease and ulcerative colitis
- Gut-selective in its target → no increase in risk of infections or malignancy

#### <u>Ustekinumab</u>

- Anti-cytokine targeting IL12/IL23
- Relatively targeted in its action
- No increase in risk of infection or malignancy compared to placebo (in RCTs)


### Management of IBD Small molecules

#### JAK inhibitors:

- Small molecule that inhibits Janus-kinase enzymes (Tofacitinib: JAK 1-3, TYK2; Filgotinib, upadacitinib: JAK1 selective inhibitors)
- Relative quick onset of action
- Increases risk of shingles, VTE and malignancy (when compared to anti-TNF)

#### Ozanimod:


- S1P modulator; results in sequestration of lymphocytes in the lymph nodes
- Slight increase in risk of cardiac arrhythmias
- Interactions with SSRI and MAOI.




D'Haens GR, et al. Lancet 2008. 371: 660-7.

## Management of ulcerative colitis

Management of UC depends on (1) extent and (2) severity of disease



## Management of ulcerative colitis



## Management of IBD Complications of therapy

- \_ Unpredictable side-effects
  - Drug hypersensitivity
  - Pancreatitis (Azathioprine / 6-MP)
  - Paradoxical flare (5-ASA)
- \_ "More" predictable side-effects
  - Infections
  - Cancer
    - Lymphoma: Approximately 5 in 10,000
    - Skin cancers (melanoma anti-TNF; NMSC thiopurines), Cervical cancer

## **Pregnancy and IBD**

- Crohn's disease and ulcerative colitis are not associated with reduced fertility (except with J-pouch)
- Disease activity at conception is an important determinant of patient outcome during pregnancy
- Most medications are safe during pregnancy (except methotrexate; steroids may cause cleft lip / palate)
- Slight increase in LBW and SGA but otherwise comparable fetal outcomes

### Health maintenance in IBD Colon cancer surveillance


Ulcerative colitis (not proctitis) and colonic Crohn's disease are at increased risk for colon cancer.

– Estimated risk at 20 years: 10%

Recommended surveillance:

- Begin at 8 years after diagnosis
- Every 1 3 years with a colonoscopy
- Newer techniques include chromoendoscopy
- Fecal DNA is under study
- No clear guidance on when to stop → depending on age and comorbidity

### Health maintenance in IBD Vaccination



Melmed GY. Am J Gastroenterol 2006 Aug;101(8):1834-40. Melmed GY. Am J Gastroenterol. 2010 Jan;105(1):148-54.



\_ Advances in diagnosis

- Non-invasive markers of inflammation
- Markers of prognosis
- Newer imaging modalities
- Changing therapeutic paradigms
  - Recognition of new goals of treatment
  - New paradigms of treatment ("Early" / "Top-down")
  - Treat to target approach

"Comprehensive" IBD care



Ashwin N Ananthakrishnan, MD, MPH aananthakrishnan@mgh.harvard.edu